160 related articles for article (PubMed ID: 8031060)
21. Pharmacokinetics of anti-HIV nucleosides in microswine.
Swagler AR; Qian MX; Gallo JM
J Pharm Pharmacol; 1991 Dec; 43(12):823-6. PubMed ID: 1687578
[TBL] [Abstract][Full Text] [Related]
22. Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes.
Pan-Zhou XR; Cretton-Scott E; Zhou XJ; Xie MY; Rahmani R; Schinazi RF; Duchin K; Sommadossi JP
Antimicrob Agents Chemother; 1997 Nov; 41(11):2502-10. PubMed ID: 9371357
[TBL] [Abstract][Full Text] [Related]
23. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
Gao WY; Shirasaka T; Johns DG; Broder S; Mitsuya H
J Clin Invest; 1993 May; 91(5):2326-33. PubMed ID: 8387546
[TBL] [Abstract][Full Text] [Related]
24. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
Tachedjian G; Mellors J; Bazmi H; Birch C; Mills J
J Virol; 1996 Oct; 70(10):7171-81. PubMed ID: 8794364
[TBL] [Abstract][Full Text] [Related]
25. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
[TBL] [Abstract][Full Text] [Related]
26. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
Mayers DL; Japour AJ; Arduino JM; Hammer SM; Reichman R; Wagner KF; Chung R; Lane J; Crumpacker CS; McLeod GX
Antimicrob Agents Chemother; 1994 Feb; 38(2):307-14. PubMed ID: 8192457
[TBL] [Abstract][Full Text] [Related]
27. Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
Cinatl J; Cinatl J; Weber B; Rabenau H; Weissflog A; Mainke M; Kornhuber B; Doerr HW
Acta Virol; 1993 Oct; 37(5):360-8. PubMed ID: 8184788
[TBL] [Abstract][Full Text] [Related]
28. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1.
Cox SW; Albert J; Wahlberg J; Uhlén M; Wahren B
AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1229-34. PubMed ID: 1520536
[TBL] [Abstract][Full Text] [Related]
29. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
[TBL] [Abstract][Full Text] [Related]
30. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Connell EV; Hsu MC; Richman DD
Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
[TBL] [Abstract][Full Text] [Related]
31. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC
Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077
[TBL] [Abstract][Full Text] [Related]
32. Reduced provirus burden and enhanced humoral immune function in AZT-treated SCID-feline mice inoculated with feline immunodeficiency virus.
Johnson CM; Selleseth DW; Ellis MN; Childers TA; Tompkins MB; Tompkins WA
Vet Immunol Immunopathol; 1995 May; 46(1-2):169-80. PubMed ID: 7618256
[TBL] [Abstract][Full Text] [Related]
33. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
34. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine.
Von Tungeln LS; Dobrovolsky VN; Bishop ME; Shaddock JG; Heflich RH; Beland FA
Mutagenesis; 2004 Jul; 19(4):307-11. PubMed ID: 15215330
[TBL] [Abstract][Full Text] [Related]
35. Effects of antiretroviral dideoxynucleosides on polymorphonuclear leukocyte function.
Roilides E; Venzon D; Pizzo PA; Rubin M
Antimicrob Agents Chemother; 1990 Sep; 34(9):1672-7. PubMed ID: 2178334
[TBL] [Abstract][Full Text] [Related]
36. Influence of human granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein (PIXY321) on the hematopoietic toxicity associated with anti-viral drugs (zidovudine and didanosine) in vitro using normal human marrow cells.
Gallicchio VS; Hughes NK
Life Sci; 1995; 57(18):PL265-73. PubMed ID: 7475901
[TBL] [Abstract][Full Text] [Related]
37. Effect of 3'azido-2',3'-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats.
Smyth NR; Bennett M; Gaskell RM; McCracken CM; Hart CA; Howe JL
Res Vet Sci; 1994 Sep; 57(2):220-4. PubMed ID: 7817010
[TBL] [Abstract][Full Text] [Related]
38. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
[TBL] [Abstract][Full Text] [Related]
39. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
Smith RA; Remington KM; Lloyd RM; Schinazi RF; North TW
J Virol; 1997 Mar; 71(3):2357-62. PubMed ID: 9032372
[TBL] [Abstract][Full Text] [Related]
40. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
